AM-Pharma B.V.

Please note: The information displayed on this page might be outdated.
AM-Pharma B.V.: Treating sepsis associated acute kidney injury (SA-AKI) w proprietary recombinant alkaline phosphatase (recAP). Raised $195M in equity and debt in 2019/2020 after results from Ph 2 in 300+ pts demonstrated robust significant improvement of 40%+ OS in recAP group. Initiated FDA/EMA/PMDA supported 1600-pts Ph 3 in Q4 2020; TL safety & futility analysis on first 400 pts Q1 2022. Expects to complete tgt enrollment & announce primary endpoint data of 28-day all-cause mortality in 2023, or as early as 2022 based on interim analyses. Investors incl Cowen Healthcare, LSP, Andera, Forbion, Ysios, Kurma Partners, ID Invest , BB Pureos Bioventures & Gilde
Sector/Industry:
Healthcare/Biotechnology
Characteristics:
Based in...
Europe
Clinical Stage
Phase III
Disease Space
Anti-inflammatory, Autoimmune, Metabolic Disorders
Industry
Biotechnology, Pharmaceuticals
Listing
Private
Website:
Profiles:
Address:
Stadsplateau 6
Utrecht, 3521
Netherlands

Company Participants at 2020 Wall Street "On Tap"

Erik van den Berg
AM-Pharma B.V., CEO
Erik has over twenty years’ experience in the pharmaceutical and biotechnology industries. Previously, as a Senior Executive at Organon he was responsible for global biotechnology business development. Prior to joining Organon, Erik worked in business and corporate development at the biotechnology company IsoTis, and as a Management Consultant at Arthur D. Little. Erik has been involved in the execution of over 20 transactions and partnerships, most recently the $600M alliance with Pfizer and raised more than €200M in equity and debt financing for biotechnology companies from seed through IPO. Erik is board member of Lava Therapeutics, Heatmatrix, Lead Pharma, Step Pharma and the Dutch biotechnology organization. Erik has an MSc in Chemistry from the University of Utrecht (NL) and an MBA from Manchester Business School (UK) both with distinction.
Juliane Bernholz, PHD
AM-Pharma B.V., Chief Operating Officer
Dr. Juliane Bernholz has over 27 years of experience working in the pharmaceutical and biotech industry in a variety of senior R&D and business development roles. She joined AM-Pharma as Chief Operating Officer in October 2019. Prior to joining AM-Pharma Juliane was a Compound Development Team Leader at Janssen R&D LLC in New Jersey, US, where she was responsible for leading the development of a next generation anticoagulant and CRISPR-Cas3 enhanced bacteriophage therapy. Before her time at Janssen, Dr. Bernholz held a number of international leadership roles in big Pharma and Biotech companies. These included Lead for International Partnering in the Diabetes Division at Sanofi-Aventis in Frankfurt, Germany where she successfully executed a cell therapy and drug discovery collaboration deal. She also served as Senior Global Program Head of the Critical Care Franchise at Novartis Pharma, where she led work on its cystic fibrosis projects. Her prior career included a variety of senior roles at Actelion, Novartis, Ciba and Sandoz. Juliane holds a PhD in Cell biology from the Biozentrum of the University of Basel, Switzerland.